Please assess the completion status of the following clinical trial:

Trial Title: Impact of an Optimised Monitored Anesthesia on the Patients' Recovery After Cytoreduction Surgery Plus HIPEC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ASA status I, II or III~* Patients older than 18 years~* HIPEC for bowel surgery with oxaliplatin + dextrose 5% for a duration of 30 min~* Duration and type of surgery requiring an epidural analgesia via an epidural catheter placed and tunnelled prior the general anesthesia induction and an arterial line placed after induction of general anesthesia.~Exclusion Criteria:~* Any allergy to one drug used in our anesthesia or HIPEC protocol~* Any contra-indication or patient's refusal for epidural placement~* Chronic arrhythmic cardiac conditions~* Chronic pain with use of opioids more than 3 times per week for 4 weeks~* Bowel occlusion~* Physical/mental incapacities~* Unexpected difficult airway requesting excessive, possibly painful airway manipulations.~* Epidural failure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Monitored group M (optimized controlled anesthesia) (Type: ACTIVE_COMPARATOR): Patients in the Monitored group M, the NOL index will guide the administration of remifentanil to keep the index between 5-25, and the desflurane will be titrated to keep a BIS index between 45 and 55. Cardiac output and stroke volume variation will be measured by the Flotrac EV1000 system. Patients will receive 250ml fluid challenges with a recommended solution as required, in order to achieve a maximal value of stroke volume.
- Control group C (standard of care anesthesia) (Type: ACTIVE_COMPARATOR): Patients in the Control group C will be managed by clinical staff according to usual practice, desflurane will be administered to keep MAC at 1, and remifentanil infusion rate will be adapted to the mean arterial blood pressure to keep it between 65 and 100.

Based on this trial design, predict the completion outcome and termination type (if applicable).